Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 501–600 of 1,001
MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.
Zhi, T., Jiang, K., Zhang, C., Xu, X., Wu, W., Nie, E., Yu, T., Zhou, X., Bao, Z., Jin, X., et al. (2017) · PubMed · Cited by 44
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Milano, G. A., Étienne-Grimaldi, M.-C., Dahan, L., Francoual, M., Spano, J., Benchimol, D., Chazal, M., Létoublon, C., André, T., Gilly, F. N., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn416 · Cited by 46
G-quadruplexes in cancer-related gene promoters: from identification to therapeutic targeting
Romano, F., Porzio, A. D., Iaccarino, N., Riccardi, G., Lorenzo, R. D., Laneri, S., Pagano, B., Amato, J., & Randazzo, A. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2271168 · Cited by 47
“The oncogenes HRAS and NRAS are the other members of the RAS gene family, and mutations in these genes are commonly observed in various human cancers [129–131].”
BackgroundDelving into somatic variation in sporadic melanoma
Walia, V., Mu, E. W., Lin, J., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 45
Zhang, L., Singh, R. R., Patel, K. P., Stingo, F. C., Routbort, M. J., You, M. J., Miranda, R. N., Garcia‐Manero, G., Kantarjian, H. M., Medeiros, L. J., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23652 · Cited by 42
Zhu, B., Ferry, C. H., Blazanin, N., Bility, M. T., Khozoie, C., Kang, B.-H., Glick, A. B., Gonzalez, F. J., & Peters, J. M. (2013) · Oncogene · doi:10.1038/onc.2013.477 · Cited by 44
Urisman, A., Levin, R. S., Gordan, J. D., Webber, J. T., Hernandez, H., Ishihama, Y., Shokat, K. M., & Burlingame, A. L. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058172 · Cited by 45
METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B
Hu, Y., Li, Y., Huang, Y., Jin, Z., Wang, C., Wang, H., & Xu, J. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173134 · Cited by 41
Carotenuto, P., Roma, C., Rachiglio, A. M., Tatangelo, F., Pinto, C., Ciardiello, F., Nappi, O., Iaffaioli, V., Botti, G., & Normanno, N. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.86 · Cited by 41
Pierpont, E. I., Kenney‐Jung, D. L., Shanley, R., Zatkalik, A. L., Whitmarsh, A. E., Kroening, S. J., Roberts, A. E., & Zenker, M. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.04.004 · Cited by 44
Paradoxical roles of FAK in tumor cell migration and metastasis
Zheng, Y., & Lu, Z. (2009) · Cell Cycle · doi:10.4161/cc.8.21.9846 · Cited by 41
Lu, Z., Cox-Hipkin, M. A., Windsor, W. T., & Boyapati, A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0179 · Cited by 41
Jafry, M., & Sidbury, R. (2020) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2020.03.010 · Cited by 40
Oh, Y.-T., Yue, P., Zhou, W., Balko, J. M., Black, E. P., Owonikoko, T. K., Khuri, F. R., & Sun, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304006 · Cited by 40
Developmental disease and cancer: Biological and clinical overlaps
Bellacosa, A. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36267 · Cited by 42
“…of this critical signaling pathway is associated with lethality, therefore all the gain-of-functionmutations in the germline of these patients are functionally and biochemically less powerful compared to the corresponding somatic mutations detected in sporadic cancer [Schubbert et al., 2007].”
BackgroundResultKRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
Herreros‐Villanueva, M., Rodrigo, M., Claver, M., Múñiz, P., Lastra, E., Girón, C. G., & del Corral, M. J. C. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0232-x · Cited by 45
Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling
Kaduwal, S., Jeong, W.-J., Park, J., Lee, K. H., Lee, Y. M., Jeon, S.-H., Lim, Y., Min, D. S., & Choi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.5173 · Cited by 41
Khan, S. A., Khan, Y. D., Ahmad, S., & Allehaibi, K. H. S. (2018) · Letters in Organic Chemistry · doi:10.2174/1570178616666181217153958 · Cited by 40
RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
Yuan, X., Tang, Z., Du, R., Yao, Z., Cheung, S., Zhang, X., Wei, J., Zhao, Y., Du, Y., Liu, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12698 · Cited by 43
“RAS and RAF are two of the most frequently mutated genes in promoting tumorigenesis (Holderfield et al ., 2014; Schubbert et al ., 2007).”
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vidimar, V., Beilhartz, G. L., Park, M., Biancucci, M., Kieffer, M. B., Gius, D. R., Melnyk, R. A., & Satchell, K. J. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000312117 · Cited by 44
Xu, W., Yang, X. C., HU, X., & Li, S. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1756 · Cited by 40
Advances in the Treatment of Metastatic Colorectal Cancer
Kurkjian, C. D., & Kummar, S. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181907ed9 · Cited by 43
Li, Q., Wu, J., Zheng, H., Liu, K., Guo, T. L., Liu, Y., Eblen, S. T., Grant, S., & Zhang, S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.030 · Cited by 40
de Mello, R. A., Madureira, P., Carvalho, L. S., Araújo, A., O'Brien, M. E. R., & Popat, S. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.177 · Cited by 43
Deep Genetic Connection Between Cancer and Developmental Disorders
Qi, H., Dong, C., Chung, W. K., Wang, K., & Shen, Y. (2016) · Human Mutation · doi:10.1002/humu.23040 · Cited by 43
CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins
Riecken, L. B., Zoch, A., Wiehl, U., Reichert, S., Scholl, I., Cui, Y., Ziemer, M., Anderegg, U., Hagel, C., & Morrison, H. (2016) · Oncotarget · doi:10.18632/oncotarget.12919 · Cited by 38
Schreiber, J., Grimbergen, L.-A., Overwater, I. E., van der Vaart, T., Stedehouder, J., Schuhmacher, A. J., Guerra, C. E., Kushner, S. A., Jaarsma, D., & Elgersma, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-01218-0 · Cited by 39
Grb2 and GRAP connect the B cell antigen receptor to Erk MAP kinase activation in human B cells
Vanshylla, K., Bartsch, C., Hitzing, C., Krümpelmann, L., Wienands, J., & Engels, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-22544-x · Cited by 41
Wang, Y., Yu, M. Y., Yang, J., Cao, D., Zhang, Y., Zhou, H., Yuan, Z., & Shen, K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00123 · Cited by 43
Liu, Z., Wang, M., Wang, H., Fang, L., & Gou, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01223 · Cited by 40
Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
Moghadamchargari, Z., Huddleston, J., Shirzadeh, M., Zheng, X., Clemmer, D. E., M. Raushel, F., Russell, D. H., & Laganowsky, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00532 · Cited by 38
Sperm sequencing reveals extensive positive selection in the male germline
Neville, M. D. C., Lawson, A. R. J., Sanghvi, R., Abascal, F., Pham, M. H., Cagan, A., Nicola, P. A., Bayzetinova, T., Baez‐Ortega, A., Roberts, K., et al. (2025) · Nature · doi:10.1038/s41586-025-09448-3 · Cited by 65
Real-time single-molecule coimmunoprecipitation of weak protein-protein interactions
Lee, H.-W., Ryu, J. Y., Yoo, J., Choi, B., Kim, K., & Yoon, T. (2013) · Nature Protocols · doi:10.1038/nprot.2013.116 · Cited by 44
Role of E3 ubiquitin ligases in lung cancer
Snoek, B. C., de Wilt, L. H., Jansen, G., & Peters, G. J. (2013) · World Journal of Clinical Oncology · doi:10.5306/wjco.v4.i3.58 · Cited by 40
Tsubaki, M., Itoh, T., Satou, T., Imano, M., Komai, M., Ogawa, N., Mukai, J., & Nishida, S. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.009 · Cited by 38
Reyes, G. X., Niederst, M. J., Cohen‐Katsenelson, K., Stender, J. D., Kunkel, M. T., Chen, M., Brognard, J., Sierecki, E., Gao, T., Nowak, D. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404221111 · Cited by 40
RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Waring, P. M., Tie, J., Maru, D. M., & Karapetis, C. S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.10.006 · Cited by 45
Fiore, D., Donnarumma, E., Roscigno, G., Iaboni, M., Russo, V. M., Affinito, A., Adamo, A., Martino, F. D., Quintavalle, C., Romano, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6968 · Cited by 37
Schöpel, M., Jockers, K. F. G., Düppe, P. M., Autzen, J., Potheraveedu, V. N., Ince, S., Yip, K. T., Heumann, R., Herrmann, C., Scherkenbeck, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401291q · Cited by 38
Ekiz, H. A., Lai, S.-C. A., Gundlapalli, H., Haroun, F., Williams, M. A., & Welm, A. L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1480286 · Cited by 39
Kondo, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.003 · Cited by 43
Suppressive function of RKTG on chemical carcinogen-induced skin carcinogenesis in mouse
Xie, X., Zhang, Y., Jiang, Y., Liu, W., Ma, H., Wang, Z., & Chen, Y. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn139 · Cited by 38
“This pathway is also implicated in many human diseases especially in cancers ( 1 ,2).”
BackgroundMcWilliams, G. D., SantaCruz, K. S., Hart, B. L., & Clericuzio, C. L. (2015) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.37379 · Cited by 38
Stjernström, A., Karlsson, C., Fernandez, O. J., Söderkvist, P., Karlsson, M. G., & Thunell, L. K. (2014) · Cancer Medicine · doi:10.1002/cam4.191 · Cited by 47
Chang, Y., Yeh, K., Hsu, N. C.-H., Lin, S., Chang, T., & Chang, J. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.10.007 · Cited by 45
Kim, J. G., Lee, S. J., Chae, Y. S., Kang, B. W., Lee, Y. J., Oh, S. Y., Kim, M. C., Kim, K. H., & Kim, S. J. (2013) · Oncology · doi:10.1159/000351234 · Cited by 36
Minase, T., Ishima, T., Itoh, K., & Hashimoto, K. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.007 · Cited by 38
Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations
Ogura, T., Kakuta, M., Yatsuoka, T., Nishimura, Y., Sakamoto, H., Yamaguchi, K., Tanabe, M., Tanaka, Y., & Akagi, K. (2014) · Oncology Reports · doi:10.3892/or.2014.3165 · Cited by 41
Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching
Harrison, R. A., Lu, J., Carrasco, M. A., Hunter, J., Manandhar, A., Gondi, S. R., Westover, K. D., & Engen, J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.017 · Cited by 37
Photosensitizers Based on G-Quadruplex Ligand for Cancer Photodynamic Therapy
Kawauchi, K., Urano, R., Kinoshita, N., Kuwamoto, S., Torii, T., Hashimoto, Y., Taniguchi, S., Tsuruta, M., & Miyoshi, D. (2020) · Genes · doi:10.3390/genes11111340 · Cited by 41
“In addition to the missense mutations, amplification of the RAS gene causes hyperactivation [54].”
BackgroundA New View of Activating Mutations in Cancer
Nussinov, R., Tsai, C., & Jang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2125 · Cited by 38
Approaches to identifying synthetic lethal interactions in cancer.
Thompson, J. M., Nguyen, Q., Singh, M., & Razorenova, O. V. (2015) · PubMed · Cited by 50
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
Al‐Kali, A., Quintás‐Cardama, A., Luthra, R., Bueso-Ramos, C., Pierce, S. A., Kadia, T. M., Borthakur, G. M., Estrov, Z. E., Jabbour, E. J., Faderl, S. H., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23410 · Cited by 37
KRAS mutant colorectal tumors: Past and present
Brand, T. M., & Wheeler, D. L. (2012) · Small GTPases · doi:10.4161/sgtp.18751 · Cited by 50
Large Granular Lymphocyte Leukemia: From Dysregulated Pathways to Therapeutic Targets
LeBlanc, F., Zhang, D., Liu, X., & Loughran, T. P. (2012) · Future Oncology · doi:10.2217/fon.12.75 · Cited by 44
Viral Oncolysis That Targets Raf-1 Signaling Control of Nuclear Transport
Riolobos, L., Valle, N., Hernando, E., Maroto, B., Kann, M., & Almendral, J. M. (2009) · Journal of Virology · doi:10.1128/jvi.01550-09 · Cited by 43
Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: A report
Siddiqi, M., Aga, S. S., Chowdhri, N., Abdullah, S., & Shah, Z. (2009) · Indian Journal of Cancer · doi:10.4103/0019-509x.52956 · Cited by 39
EGFR phosphorylates FAM129B to promote Ras activation
Ji, H., Lee, J.-H., Wang, Y., Pang, Y., Zhang, T., Xia, Y., Zhong, L., Lyu, J., & Lu, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517112113 · Cited by 38
p21-Activated Kinase Inhibitors
Rudolph, J., Crawford, J. J., Hoeflich, K. P., & Chernoff, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00007-x · Cited by 37
Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
Marazioti, A., Lilis, I., Vreka, M., Apostolopoulou, H., Kalogeropoulou, A., Giopanou, I., Giotopoulou, G. A., Krontira, A. C., Iliopoulou, M. P., Kanellakis, N. I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03051-z · Cited by 39
Wan, X., Wang, A.-Q., Cao, J., Dong, Z.-C., Li, N., Yang, S., Sun, M., Li, Z., & Luo, S.-X. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.808 · Cited by 41
A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
Guijarro-Hernández, A., & Vizmanos, J. L. (2021) · Cancers · doi:10.3390/cancers13050984 · Cited by 44
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 52
Leung, L., Radulovich, N., Zhu, C., Wang, D. Y. Q., To, C., Ibrahimov, E., & Tsao, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084366 · Cited by 40
Villavicencio, A. N. P., Aguilar, G., Argüello, G., Dunner, C., Gabler, F., Soto, E., Fancy Gaete, V., Peñaloza, P., Celis, M., & Rojas, C. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.12.022 · Cited by 36
“activation [17–23].”
Zhong, J., Zhao, M., Luo, Q., Ma, Y., Liu, J., Wang, J., Yang, M., Yuan, X., Sang, J., & Huang, C. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1418-4 · Cited by 37
Determining protein stability in cell lysates by pulse proteolysis and Western blotting
Kim, M., Jiao, S., & Park, C. (2009) · Protein Science · doi:10.1002/pro.115 · Cited by 43
Identification of Tumorigenic Cells in KrasG12D -Induced Lung Adenocarcinoma
Cho, H.-C., Lai, C.-Y., Shao, L., & Yu, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0903 · Cited by 39
Detectable Clonal Mosaicism in the Human Genome
Machiela, M. J., & Chanock, S. J. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.09.001 · Cited by 36
Roles of Tetrahydrobiopterin in Promoting Tumor Angiogenesis
Chen, L., Zeng, X., Wang, J., Briggs, S. S., O’Neill, E., Li, J., Leek, R., Kerr, D. J., Harris, A. L., & Cai, S. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100025 · Cited by 40
Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 38
Calaf (2009) · International Journal of Oncology · doi:10.3892/ijo_00000421 · Cited by 35
Duval, D., Lardeux, A., Tourneau, T. L., Norris, R. A., Markwald, R. R., Sauzeau, V., Probst, V., Marec, H. L., Levine, R. A., Schott, J., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.10.022 · Cited by 35
Posch, C., Sanlorenzo, M., Vujic, I., Osés-Prieto, J. A., Cholewa, B. D., Kim, S. T., Ma, J. A., Lai, K., Zekhtser, M., Esteve‐Puig, R., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.05.098 · Cited by 40
The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
Mokhlis, H. A., Bayraktar, R., Kabil, N. N., Caner, A., Kahraman, N., Rodriguez‐Aguayo, C., Zambalde, É. P., Sheng, J., Karagoz, K., Kanlikilicer, P., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.019 · Cited by 38
“Activating KRAS gene mutations occur in one-third of human cancers, including adenocarcinomas of the pancreas (80%–90%), colon (45%), and lung (30%–50%),(7) and also in biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia,(8,9) and breast cancer.(10) Although…”
BackgroundMAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
Caeser, R., Hulton, C. H., Costa, E. A., Durani, V., Little, M., Chen, X., Tischfield, S. E., Asher, M., Kombak, F. E., Chavan, S. S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103224 · Cited by 41
Lito, P., Mets, B. D., Kleff, S., O’Reilly, S., Maher, V. M., & McCormick, J. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m709046200 · Cited by 41
Huang, S., Wang, D., Zhang, S., Huang, X., Wang, D., Ijaz, M., & Shi, Y. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3393-7 · Cited by 35
Melanoma Mutagenesis and Aberrant Cell Signaling
Bello, D. M., Ariyan, C. E., & Carvajal, R. D. (2013) · Cancer Control · doi:10.1177/107327481302000404 · Cited by 40
Targeting CK2-driven non-oncogene addiction in B-cell tumors
Mandato, E., Manni, S., Zaffino, F., Semenzato, G., & Piazza, F. (2016) · Oncogene · doi:10.1038/onc.2016.86 · Cited by 35
Progress towards molecular-based management of childhood Langerhans cell histiocytosis
Héritier, S., Emile, J., Hélias‐Rodzewicz, Z., & Donadieu, J. (2019) · Archives de Pédiatrie · doi:10.1016/j.arcped.2019.05.015 · Cited by 35
“It was also shown that the BRAFV600E mutation was lethal in embryos [26].”
BackgroundLiu, Y., Feng, W., Gu, S., Wang, H., Zhang, Y., Chen, W., Xu, W., Chen, L., Gong, A., & Xu, M. (2019) · Europe PMC (PubMed Central) · Cited by 34
Nyström, A., Ekvall, S., Strömberg, B., Holmström, G. E., Thuresson, A., Annerén, G., & Bondeson, M.-L. (2008) · Acta Paediatrica · doi:10.1111/j.1651-2227.2008.01170.x · Cited by 34
Rack1 protects N-terminal phosphorylated c-Jun from Fbw7-mediated degradation
Zhang, J., Zhu, F., Li, X., Dong, Z., Xu, Y., Peng, C., Li, S., Cho, Y.-Y., Yao, K., Zykova, T. A., et al. (2011) · Oncogene · doi:10.1038/onc.2011.369 · Cited by 33
Protein Kinase Cδ Is a Therapeutic Target in Malignant Melanoma with NRAS Mutation
Takashima, A., English, B., Chen, Z., Cao, J., Cui, R., Williams, R. M., & Faller, D. V. (2014) · ACS Chemical Biology · doi:10.1021/cb400837t · Cited by 34
de la Vega, M., Burrows, J. F., McFarlane, C., Govender, U., Scott, C. J., & Johnston, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081448 · Cited by 34
Barceló, C., Paco, N., Beckett, A. J., Alvarez-Moya, B., Garrido, E., Gelabert, M., Tebar, F., Jaumot, M., Prior, I. A., & Agell, N. (2013) · Journal of Cell Science · doi:10.1242/jcs.123737 · Cited by 35
New innovations: Therapeutic opportunities for intellectual disabilities
Picker, J. D., & Walsh, C. A. (2013) · Annals of Neurology · doi:10.1002/ana.24002 · Cited by 41
Arena, S., Isella, C., Martini, M., de Marco, A., Médico, E., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1126 · Cited by 38
Experimental evidence for cancer resistance in a bat species
Hua, R., Ma, Y.-S., Yang, L., Hao, J., Hua, Q., Shi, L., Yao, X., Zhi, H.-Y., & Liu, Z. (2024) · Nature Communications · doi:10.1038/s41467-024-45767-1 · Cited by 41
“…the oncogenic HRAS(G12V) is the most common cancer-associated substitution and is also commonly used to induce malignant transformation of cells 11 , particularly in non-model organisms like naked mole-rats and blind mole-rats 12,13 , neoplastic transformation of cells may require species-or…”
Negi, A., Ramarao, P., & Kumar, R. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557511313050004 · Cited by 33
Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-RasG13D
Palmioli, A., Sacco, E., Airoldi, C., Nicolantonio, F. D., D’Urzo, A., Shirasawa, S., Sasazuki, T., Domizio, A. D., GIOIA, L. D., Martegani, E., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.069 · Cited by 33
Kim, E. J., Wang, Y., Kim, S. J., Bornhorst, M., Jecrois, E. S., Anthony, T. E., Wang, C., Li, Y. E., Guan, J., Murphy, G. G., et al. (2014) · eLife · doi:10.7554/elife.05151 · Cited by 34
N‐Ras or K‐Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells
Mor, A., Keren, G., Kloog, Y., & George, J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838292 · Cited by 36
Rasopathies: Developmental Disorders That Predispose to Cancer and Skin Manifestations
Hernández‐Martín, A., & Torrelo, A. (2011) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2011.02.002 · Cited by 33
Leoncini, P. P., Bertaina, A., Papaioannou, D., Flotho, C., Masetti, R., Bresolin, S., Menna, G., Santoro, N., Zecca, M., Basso, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10577 · Cited by 34
Kalimutho, M., Bain, A. L., Mukherjee, B., Nag, P., Nanayakkara, D. M., Harten, S. K., Harris, J. L., Subramanian, G. N., Sinha, D., Shirasawa, S., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12040 · Cited by 38
Targeting LINC00673 expression triggers cellular senescence in lung cancer
Roth, A., Boulay, K., Groß, M., Polycarpou‐Schwarz, M., Mallette, F. A., Regnier, M., Bida, O., Ginsberg, D., Warth, A., Schnabel, P. A., et al. (2018) · RNA Biology · doi:10.1080/15476286.2018.1553481 · Cited by 36
Luo, Y., He, Y., Ye, X., Song, J., Wang, Q., Yu-kui, L., & Xie, X. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-018-00570-4 · Cited by 34
RetractedSarkar, D., Olejniczak, E. T., Phan, J., Coker, J. A., Sai, J., Arnold, A. L., Beesetty, Y., Waterson, A. G., & Fesik, S. W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00511 · Cited by 33
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.